Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
shakedown.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
A community for live music fans with roots in the jam scene. Shakedown Social is run by a team of volunteers (led by @clifff and @sethadam1) and funded by donations.

Administered by:

Server stats:

285
active users

shakedown.social: AboutStatusProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.7

#cardiovascular

1 post1 participant0 posts today
Public
Auscandoc

Forehead Wrinkles and risk of all-cause and cardiovascular mortality over 20- year follow-up in working population: VISAT study | European Heart Journal | Oxford Academic academic.oup.com/eurheartj/art academic.oup.com/eurheartj/art
Stop frowning.

“In a working population, the number and the depth of forehead #wrinkles were associated with cardiovascular mortality regardless chronological age and classical #cardiovascular risk factors.”

Public
Auscandoc

Sociodemographic and Population Exposure to Upstream Oil and Gas Operations in Canada mdpi.com/1660-4601/21/12/1692 “study on the health impacts of pollution from Alberta's #OilAndGas sector has found the odds of having negative #respiratory and #cardiovascular health outcomes increase by nine to 21 per cent, depending on the number of oil and gas wells a person lives near.”

MDPISociodemographic and Population Exposure to Upstream Oil and Gas Operations in CanadaCanada, as one of the largest oil and gas producer in the world, is responsible for large emissions of methane, a powerful greenhouse gas. At low levels, methane is not a direct threat to human health; however, human health is affected by exposure to pollutants co-emitted with methane. The objectives of this research were to estimate and map pollutants emitted by the oil and gas industry, to assess the demographic of the population exposed to oil and gas activities, and to characterize the impact of well density on cardiovascular- and respiratory-related outcomes with a focus on Alberta. We estimated that ~13% and 3% people in Alberta reside, respectively, within 1.5 km of an active well and 1.5 km of a flare. Our analysis suggests that racial and socioeconomic disparities exist in residential proximity to active wells, with people of Aboriginal identity and people with less education being more exposed to active wells than the general population. We found increased odds of cardiovascular-related (1.13–1.29 for low active well density) and respiratory-related (1.07–1.19 for low active well density) outcomes with exposure to wells. Close to 100 countries produce oil and gas, making this a global issue. There is an important need for additional studies from other producing jurisdictions outside the United States.
Public
Auscandoc

“Report suggests potential #ExcessMortality in the general population of up to 3% for the US by 2033 and 2.5% in the UK, the longest period of elevated peacetime excess mortality in the US
Key driver of excess mortality is the lingering impact of #COVID19; both as a direct cause of death, and as a contributor to #cardiovascular mortality
Reducing the impact of COVID-19 on elderly and vulnerable populations will be key to excess mortality returning to zero” med-mastodon.com/@cbarbermd/11

Med-MastodonCarolyn Barber, MD (@cbarbermd@med-mastodon.com)According to Swiss Re Institute's report, “The future of excess mortality after #COVID , if the ongoing impact of the disease is not curtailed, excess mortality rates may remain up to 3% higher than pre-pandemic levels in the US and 2.5% in the UK by 2033.” https://shorturl.at/eoFWt #press
Public
Auscandoc

News Details novonordisk.com/news-and-media novonordisk.com/content/nncorp “The key objective of SOUL was to demonstrate that oral #semaglutide lowers the risk of major adverse #cardiovascular events (a composite endpoint consisting of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) compared to placebo, both added to standard of care in patients with type 2 #diabetes and established CVD and/or CKD.”

#Rybelsus has lift off @ChristosArgyrop ?

Novo NordiskNews Details
Continued thread
Public
Auscandoc

In addition, when considering post-COVID #thromboembolic and #cardiovascular complications as outcomes of interest, recently published data have shown that vaccination with any COVID-19 first vaccine dose (ChAdOx1, BNT162b2, and mRNA-1273) is associated with reduced risk of post-acute heart failure, venous thromboembolism, and arterial thrombosis”. (2/2)

Public
Chuck Darwin

#Wegovy®, #Zepbound®, and similar medications continue to gain attention for effectively treating #obesity, and now there is discussion—with research underway—about their potential for improving certain #surgical outcomes.

The brand-name medications mentioned above belong to a class called GLP-1 (glucagon-like peptide-1) agonists. #GLP-1s mimic the actions of the GLP-1 hormone, which is secreted in the gut and sends an “I’m full” signal to the brain after you eat.

GLP-1 medications aren’t new. @Ozempic® (generic name: #semaglutide) received approval from the U.S. Food and Drug Administration (FDA) to treat type 2 diabetes in 2017.

After its weight-loss effects were studied, semaglutide (at a higher dose and sold under the name Wegovy) was approved by the FDA as an anti-obesity medication in 2021, and others have since followed.

Most recently, the FDA approved Wegovy for patients with #cardiovascular #disease and obesity or overweight after a study showed that those taking the medication had a lower overall risk of major cardiac events, such as heart attack, stroke, or cardiovascular-related death.

Now, some Yale Medicine surgeons believe, based on their ongoing research, that taking anti-obesity medications before and sometimes after total #joint #replacement and #bariatric #surgery can be beneficial.

“These medications have been transformative, in terms of expanding the pool of people who can safely undergo joint replacement surgery,” says Daniel Wiznia, MD, a Yale Medicine orthopaedic surgeon and co-director of the Avascular Necrosis Program.

“These anti-obesity medications are game-changers; they are changing the way people practice medicine.”

Often, patients who need a total hip or knee replacement must delay surgery until they lose enough weight to meet specific body mass index ( #BMI ) standards.
This is important in protecting the patient’s health.

“Weight increases a patient’s risk of postoperative complications, including wound-healing problems, stroke, heart attack, blood clots, and infection,” he says.

However, having patients take a GLP-1 medication before surgery, as well as improving their diet, has allowed more patients to reach a safe preoperative BMI, Dr. Wiznia says.

yalemedicine.org/news/anti-obe

Public
Scientific Frontline

#Rice is already known to contain more inorganic #arsenic than other cereals. Cooking rice with water containing more than 10 µg L-1 (parts per billion) inorganic arsenic amplifies the risk of arsenic exposure Long-term exposure to inorganic arsenic in water can cause serious health problems such as #cancers, #diabetes and #pulmonary and #cardiovascular diseases
#Environmental #NutritionalScience #sflorg
sflorg.com/2024/03/en03212402.

www.sflorg.comMillions are at risk using high arsenic water for cookingRice is one of the major cereal crops in the world, contributing to the dietary energy and nutrition of more than half of the world's population
Continued thread
Public *
Auscandoc

Researchers analysed health records from more than 20 million people across the UK, Spain and Estonia and found consistent evidence that the jabs protected against serious #cardiovascular complications of the disease.” (2/2)

heart.bmj.com/content/early/20

Heart · The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complicationsObjective To study the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications. Methods We conducted a staggered cohort study based on national vaccination campaigns using electronic health records from the UK, Spain and Estonia. Vaccine rollout was grouped into four stages with predefined enrolment periods. Each stage included all individuals eligible for vaccination, with no previous SARS-CoV-2 infection or COVID-19 vaccine at the start date. Vaccination status was used as a time-varying exposure. Outcomes included heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) recorded in four time windows after SARS-CoV-2 infection: 0–30, 31–90, 91–180 and 181–365 days. Propensity score overlap weighting and empirical calibration were used to minimise observed and unobserved confounding, respectively. Fine-Gray models estimated subdistribution hazard ratios (sHR). Random effect meta-analyses were conducted across staggered cohorts and databases. Results The study included 10.17 million vaccinated and 10.39 million unvaccinated people. Vaccination was associated with reduced risks of acute (30-day) and post-acute COVID-19 VTE, ATE and HF: for example, meta-analytic sHR of 0.22 (95% CI 0.17 to 0.29), 0.53 (0.44 to 0.63) and 0.45 (0.38 to 0.53), respectively, for 0–30 days after SARS-CoV-2 infection, while in the 91–180 days sHR were 0.53 (0.40 to 0.70), 0.72 (0.58 to 0.88) and 0.61 (0.51 to 0.73), respectively. Conclusions COVID-19 vaccination reduced the risk of post-COVID-19 cardiac and thromboembolic outcomes. These effects were more pronounced for acute COVID-19 outcomes, consistent with known reductions in disease severity following breakthrough versus unvaccinated SARS-CoV-2 infection. Data may be obtained from a third party and are not publicly available. CPRD: CPRD data were obtained under the CPRD multi-study license held by the University of Oxford after Research Data Governance (RDG) approval. Direct data sharing is not allowed. SIDIAP: In accordance with current European and national law, the data used in this study is only available for the researchers participating in this study. Thus, we are not allowed to distribute or make publicly available the data to other parties. However, researchers from public institutions can request data from SIDIAP if they comply with certain requirements. Further information is available online (<https://www.sidiap.org/index.php/menu-solicitudesen/application-proccedure>) or by contacting SIDIAP (sidiap@idiapjgol.org). CORIVA: CORIVA data were obtained under the approval of Research Ethics Committee of the University of Tartu and the patient level data sharing is not allowed. All analyses in this study were conducted in a federated manner, where analytical code and aggregated (anonymised) results were shared, but no patient-level data was transferred across the collaborating institutions.
ExploreLive feeds
About